Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 45 member companies with pharmaceutical R&D capability.
As of June 2020, RDPAC member companies have established 47 manufacturing facilities and 25 R&D centers in mainland China. From July 2015 to June 2020, RDPAC member companies have introduced more than 206 innovative drugs to China market.
HEALTHIER CHINA THROUGH INNOVATION
To be a valued partner in delivering the “Healthy China” goal to improve the health and quality of life of people in China:
• Provide high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
• Commit to securing patients timely access to innovative & high quality drugs;
• Achieve the highest standard of integrity for ethical research and business practice;
• Contribute to the growth of the biopharmaceutical sector in China;
• Support the development of a sustainable healthcare system in China.
Abbott
Abbvie
Allergan
ALK
Amgen
Aspen
Astellas
Astrazeneca
Baxter
Bayer
Biogen
Boehringer-Ingelheim
Bristol-Myers Squibb
Chiesi
Chugai
Daiichi Sankyo
Eisai
Eli Lilly
Ethypharm
Ferring
Gedeon Richter
Gilead
GSK
Helsinn
Ipsen
Janssen
Kyowa Kirin
LEO Pharma China
Lundbeck
Menarini
Merck
MSD
Novartis
Novo Nordisk
Organon
Pfizer
Roche
Sanofi
Santen
Servier
Sumitomo
Takeda
Teva
UCB
Zambon
A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.
As the first pharmaceutical industry organization in China to attach great importance to compliance, and as a member and an active player of the global pharmaceutical industry association network, RDPAC has continuously strived to reflect the latest standards of international pharmaceutical industry associations, using the Code of Practice of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) as its foundation in doing so. At the same time, RDPAC has kept abreast of the latest requirements of Chinese laws, regulations and policies, and the cutting-edge developments in business practices and compliance controls in China's pharmaceutical industry, providing member companies with the latest and highest standards of compliance based on best practice. Adherence to the RDPAC Code of Practice has also been made a precondition for companies to join RDPAC. Furthermore, RDPAC is supportive of the member companies’ intention to develop and implement their more stringent in-house codes of practice on this basis.